drugset / Trial / NCT02753504

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

NCT02753504

Phase 1 Completed 24 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519

Timeline

Start
2016-04
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ROCACETRAPIB Small molecule 50 mg Oral
Subject ROCACETRAPIB Small molecule 100 mg Oral
Subject ROCACETRAPIB Small molecule 200 mg Oral

Indications